Case 4: Metastatic EGFR+ NSCLC Progressing on Osimertinib

Case 4: Metastatic EGFR+ NSCLC Progressing on Osimertinib

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

2023 Best of Lung: Targeted Therapies in Lung Cancer

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLCПодробнее

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC

Case 2: Osimertinib in EGFR-Mutated Lung CancerПодробнее

Case 2: Osimertinib in EGFR-Mutated Lung Cancer

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line TreatmentПодробнее

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

Case 4: Upfront Osimertinib in Metastatic EGFR+ NSCLCПодробнее

Case 4: Upfront Osimertinib in Metastatic EGFR+ NSCLC

Case 4: Treating EGFR+ NSCLC After OsimertinibПодробнее

Case 4: Treating EGFR+ NSCLC After Osimertinib

Case 4: EGFR Mutation Analysis Post-OsimertinibПодробнее

Case 4: EGFR Mutation Analysis Post-Osimertinib

События